1. White JW. I. The Results of Double Castration in Hypertrophy. Ann Surg. 1895 Jul;22(1):1-80. doi: 10.1097/00000658-189507000-00001. PMID: 17860184; PMCID: PMC1424827.
2. Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020 Jan;113(1):21-50. doi: 10.1016/j.fertnstert.2019.11.030. PMID: 32033719.
3. Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol. 1979;121:755–60
4. Meert T, Baten E, van Renterghem K: Clinical Importance of Histopathological Inflammation in Patients with Lower Urinary Tract Symptoms Due to Benign Hyperplasia: A Prospective Study of 222 Patients. Curr Urol 2016;10:150-153. doi: 10.1159/000447170
5. Nickel JC, Roehrborn CG, Castro-Santamaria R, Freedland SJ, Moreira DM. Chronic Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention. J Urol. 2016 Nov;196(5):1493-1498. doi: 10.1016/j.juro.2016.06.090. Epub 2016 Jul 1. PMID: 27378134.
6. Nygård LH, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ. The effect of non-steroidal anti-inflammatory drugs on risk of benign hyperplasia. 2017 Jun;77(9):1029-1035. doi: 10.1002/pros.23359. PMID: 28480542.
7. Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology. 1999 Dec;54(6):960-3. doi: 10.1016/s0090-4295(99)00358-1. PMID: 10604689.
8. Shoskes DA. Phytotherapy in chronic prostatitis. Urology. 2002 Dec;60(6 Suppl):35-7; discussion 37. doi: 10.1016/s0090-4295(02)02383-x. PMID: 12521591.
9. Ward AB, Mir H, Kapur N, Gales DN, Carriere PP, Singh S. Quercetin inhibits cancer by attenuating cell survival and inhibiting anti-apoptotic pathways. World J Surg Oncol. 2018 Jun 14;16(1):108. doi: 10.1186/s12957-018-1400-z. PMID: 29898731; PMCID: PMC6001031.
10. Meng LQ, Yang FY, Wang MS, Shi BK, Chen DX, Chen D, Zhou Q, He QB, Ma LX, Cheng WL, Xing NZ. Quercetin protects against chronic prostatitis in rat model through NF-κB and MAPK signaling pathways. 2018 Aug;78(11):790-800. doi: 10.1002/pros.23536. Epub 2018 Apr 13. PMID: 29654614.
11. Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;1998(1):CD001044. doi: 10.1002/14651858.CD001044. PMID: 11869585; PMCID: PMC7032619.
12. Ishani A, MacDonald R, Nelson D, et al. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med. 2000 Dec 1;109(8):654-64.
13. Breza J, Dzurny O, Borowka A, et al. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr Med Res Opin. 1998;14(3):127-39.
14. Integr Med (Encinitas). 2015;14(4):35-48.
15. Gallardo-Williams MT, Chapin RE, King PE, et al. Boron supplementation inhibits the growth and local expression of IGF-1 in human adenocarcinoma (LNCaP) tumors in nude mice. Toxicol Pathol. 2004;32(1):73-8.
16. Walker AF, Bundy R, Hicks SM, Middleton RW. Bromelain reduces mild acute knee pain and improves well-being in a dose-dependent fashion in an open study of otherwise healthy adults. Phytomedicine. 2002 Dec;9(8):681-6. doi: 10.1078/094471102321621269. PMID: 12587686.
17. Oelke M, Berges R, Schlafke S, et al. Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies. World J Urol. 2014;32(5):1149-54.
18. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002(3):Cd001423.
19. Phytother Res. 2013;27(2):218-26.
20. Penugonda K, Lindshield BL. Fatty acid and phytosterol content of commercial saw palmetto supplements. Nutrients. 2013;5(9):3617-3633. Published 2013 Sep 13. doi:10.3390/nu5093617
21. beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review.
https://www.ncbi.nlm.nih.gov/pubmed/10368239
22. Hong H, Kim CS, Maeng S. Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutr Res Pract. 2009;3(4):323-327. doi:10.4162/nrp.2009.3.4.323
23. Sogabe H and Terado T. (2001). Open Clinical Study of Effects of Pumpkin Seed Extract/ Soybean Germ Extract Mixture- containing Processed Food on Nocturia. Jpn J Med Pharm Sci. Nov;46(5):727-37. Available at: http://www.kvinnohalsa.se/pdf/swe_pilot.pdf. Accessed August 15, 2008.
24. Hong H, Kim CS, Maeng S. Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutr Res Pract. 2009;3(4):323-7.
25. Lopatkin N, Sivkov A, Schlafke S, et al. Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms--long-term follow-up of a placebo-controlled, double-blind, multicenter trial. Int Urol Nephrol. 2007;39(4):1137-46.
26. Teucher T, Obertreis B, Ruttkowski T, Schmitz H. Zytokin-Sekretion im Vollblut gesunder Probanden nach oraler Einnahme eines Urtica dioica L.-Blattextraktes [Cytokine secretion in whole blood of healthy subjects following oral administration of Urtica dioica L. plant extract]. Arzneimittelforschung. 1996 Sep;46(9):906-10. German. PMID: 8967906.
27. Nahata A, Dixit VK. Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats. Andrologia. 2012 May;44 Suppl 1:396-409. doi: 10.1111/j.1439-0272.2011.01197.x. Epub 2011 Aug 2. PMID: 21806658.
28. Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother. 2005;5(4):1-11. PMID: 16635963.
29. Oelke M, Berges R, Schlafke S, et al. Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies. World J Urol. 2014;32(5):1149-54.